AcelRx Pharmaceuticals

375 articles with AcelRx Pharmaceuticals

• AcelRx Pharmaceuticals Reports Third Quarter 2019 Financial Results

  11/6/2019

  Exceeded 125 REMS-certified facilities two months ahead of year-end goal

• AcelRx Pharmaceuticals to Present at Credit Suisse 28th Annual Healthcare Conference

  11/5/2019

  AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, announced that management will be presenting at the Credit Suisse 28th Annual Healthcare Conference to be held November 11 – 13.

• AcelRx to announce third quarter 2019 results and provide an update on the company's business on Wednesday, November 6th, 2019

  10/28/2019

   AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on Wednesday, November 6, 2019.

• Dr. TJ Gan to Present at the 2019 Annual Meeting of the American Society of Anesthesiologists

  10/16/2019

  AcelRx Pharmaceuticals, Inc. announced an upcoming presentation at the Annual Meeting of the American Society of Anesthesiologists.

• AcelRx Pharmaceuticals Selected to Present at the 2019 Military Health System Research Symposium

  8/15/2019

  AcelRx was selected to present at one of the two plenary sessions at this year's meeting. 

• AcelRx Pharmaceuticals Reports Second Quarter 2019 Financial Results

  8/5/2019

  AcelRx Pharmaceuticals, Inc.,, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, reported its second quarter 2019 financial results.

• AcelRx to announce second quarter 2019 results and provide an update on the company's business on Monday, August 5th, 2019

  8/2/2019

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Monday, August 5th, 2019.

• AcelRx added to the Russell 2000® and 3000® indexes

  7/1/2019

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings,  today announced that the Company has been added as a member of the Russell 2000® and Russell 3000® Indexes effective at the opening of trading today, July 1, 2019.

• AcelRx announces the closing of a $25 million senior secured debt facility

  6/3/2019

  AcelRx Pharmaceuticals, Inc. announced the closing of a $25 million senior secured debt facility with Oxford Finance LLC, a specialty finance firm providing senior debt to life sciences and healthcare services companies worldwide.

• AcelRx Pharmaceuticals Reports First Quarter 2019 Financial Results

  5/8/2019

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2019 financial results.

• AcelRx to announce first quarter 2019 results and provide an update on the company's business on Wednesday, May 8th, 2019

  4/25/2019

  AcelRx Pharmaceuticals, Inc. announced that it will release first quarter financial results after market close on Wednesday, May 8th, 2019.

• AcelRx Pharmaceutical's pooled safety results for sufentanil sublingual tablets (DSUVIA) selected for presentation at 44th Annual Regional Anesthesiology & Acute Pain Medicine Meeting

  4/11/2019

  AcelRx Pharmaceuticals, Inc. announced an abstract about the safety of DSUVIA™ has been selected, as one of the highest scoring abstracts, for a moderated presentation at the 44th Annual Regional Anesthesiology & Acute Pain Medicine Meeting taking place from April 11-13 in Las Vegas, Nevada.

• AcelRx Pharmaceuticals to Present at Oppenheimer & Co. Inc. 29th Annual Healthcare Conference

  3/11/2019

  AcelRx Pharmaceuticals, Inc. announced that management will be presenting at the Oppenheimer 29th Annual Healthcare Conference to be held March 19 – 20.

• AcelRx Pharmaceuticals Announces Commercial Launch of DSUVIA and Reports Fourth Quarter and Full Year 2018 Financial Results

  3/7/2019

  DSUVIA now available for use in certified medically supervised healthcare settings, with initial shipments to wholesalers completed in the second half of February 2019

• AcelRx to announce fourth quarter 2018 results and provide a corporate update on Thursday, March 7th, 2019

  2/22/2019

  AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that it will release fourth quarter and annual financial results after market close on Thursday, March 7th, 2019.

• AcelRx Pharmaceutical's sufentanil sublingual tablet (DSUVIA) to be highlighted during a presentation at the Boswick Burn and Wound Symposium

  1/31/2019

  The symposium will take place February 2-7, 2019.

• AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain

  1/7/2019

  Over 800 patients from AcelRx studies supporting DSUVIA™ approval were included in the pooled safety analysis

• 

  7 Biotech Trends to Look Out for in 2019

  12/26/2018

  As 2018 comes to a close, analysts, journalists, investors and industry-watchers are studying their crystal balls to see what trends to watch in the upcoming year. Here are 7 trends most likely to be hitting the news cycle.

• AcelRx Pharmaceuticals added to the NASDAQ Biotechnology Index (NBI)

  12/18/2018

  AcelRx Pharmaceuticals, Inc., announced it has been selected for addition to the NASDAQ Biotechnology Index®

• AcelRx Pharmaceuticals to Host Analyst and Investor Day on December 11

  11/29/2018

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx),  a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host an analyst and investor day on Tuesday, December 11, 2018 from 8:30 a.m. ET to 11:00 a.m. ET in New York City.